Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma
نویسندگان
چکیده
منابع مشابه
Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy
Background. Advanced age and immune dysfunction are risk factors for cutaneous squamous cell carcinoma (cSCC) and often render patients with locally-advanced disease medically inoperable or surgically unresectable, but potentially curable with radiotherapy. Concurrent chemotherapy and radiotherapy may not be well tolerated in this population, but another systemic therapy may improve disease con...
متن کاملConcurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck
BACKGROUND Concurrent chemoradiation is the standard treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC).The present study was carried out to assess the feasibility and efficacy of low-dose gemcitabine as a radiosensitizer when used during radical therapeutic management of patients with locally advanced HNSCC. PATIENTS AND METHODS Fifty-two patients with locally...
متن کاملCytodiagnosis of Cutaneous Basal and Squamous Cell Carcinoma
Background and Objective: Cutaneous cytology is the study of scraping or smears obtained from skin lesions. Although not commonly employed, cutaneous cytology has been a useful tool for clinicians due to simplified procedures and high sensitivity and specificity of presurgical clinical diagnosis of commo...
متن کاملCurrent Management of Advanced Resectable Oral Cavity Squamous Cell Carcinoma
The oral cavity is the most common site of head and neck squamous cell carcinoma, a disease which results in significant morbidity and mortality worldwide. Though the primary modality of treatment for patients with oral cavity cancer remains surgical resection, many patients present with advanced disease and are thus treated using a multi-disciplinary approach. Patients with extracapsular sprea...
متن کاملConcurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
IMPORTANCE Vismodegib is a targeted agent recently approved for treating patients who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integrated into existing therapy for advanced BCC as it becomes increasingly used. Improved understanding of how vismodegib interacts with other treatment modalities, including radiotherapy, would help optimize multidiscip...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Dermatology
سال: 2019
ISSN: 1167-1122,1952-4013
DOI: 10.1684/ejd.2019.3671